



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	66.15
Trade Time:	3:09 PM ET Oct 22, 2018
Change:	1.75  (+2.716%)
Day Range	63.28 - 66.40
52-Week Range	26.54 - 72.83
Volume	122,053


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Oct 22, 2018*  
[Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients](#)
- Oct 9, 2018*  
[New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment](#)
- Sep 28, 2018*  
[New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® \(GPS™\) Test](#)
- Sep 7, 2018*  
[German Health Technology Assessment Body \(IQWiG\) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results](#)
- Aug 2, 2018*  
[Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress](#)

## Financials & Filings [\[ View all \]](#)

- Mar 14, 2018*  
[Annual Report \(10-K\)](#)
- Apr 27, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 7, 2018*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2018*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)

